Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Forest Laboratories
NCT07523048 · Major Depressive Disorder (MDD)
NCT07226661 · Major Depressive Disorder (MDD)
NCT07115329 · Major Depressive Disorder
NCT06793397 · Major Depressive Disorder (MDD), Depression in Adults, and more
NCT06132581 · Major Depressive Disorder, Anhedonia
Forest Investigative Site
Phoenix, Arizona
Forest Investigative Site
Scottsdale, Arizona
Forest Investigative Site
Beverly Hills, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions